SCHEMBL287535

SCHEMBL287535

C[C@@H](N)c1ccccc1I

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
NFKB1 P19838 1/20 0.45
PNMT P11086 1/20 0.45
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
GLA P06280 1/20 0.43
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.35
TAAR1 Q96RJ0 3/20 0.34
SLC6A2 P23975 2/20 0.34
MAOA P21397 1/20 0.34
SLC6A4 P31645 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5581682 1.00 CYP2D6 (0.45) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL1711365 1.00 CYP2D6 (0.45) CYP2D6CYP1A2CYP3A4NFKB1PNMT
Water SCHEMBL11017550 0.98 CYP2D6 (0.43) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL10886657 0.93 CYP2D6 (0.41) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL7198639 0.82 KDM4E (0.52) CYP2D6CYP3A4NFKB1LMNAALDH1A1
SCHEMBL27218519 0.81 DPP4 (0.33) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL11295470 0.81 DPP4 (0.33) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL30678523 0.81 CYP2D6 (0.54) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL14395925 0.81 CYP2D6 (0.54) CYP2D6CYP1A2CYP3A4NFKB1PNMT
SCHEMBL30678522 0.81 CYP2D6 (0.54) CYP2D6CYP1A2CYP3A4NFKB1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2220093-A2 PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF Dr. Reddy's Laboratories Ltd. (IN) 2010-08-25 EP claimed
WO-2009085990-A2 PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF DR. REDDY'S LABORATORIES LIMITED (IN) 2009-07-09 WO claimed
EP-2069320-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES Teva Pharmaceutical Industries Ltd. (IL) 2009-06-17 EP claimed
WO-2008151170-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-12-11 WO claimed
WO-2015049629-A1 IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS Piramal Enterprises Limited (IN) 2015-04-09 WO disclosed
EP-2751081-A1 POLYMORPHIC FORM OF PITAVASTATIN CALCIUM Farma GRS, d.o.o. (SI) 2014-07-09 EP disclosed
WO-2013037838-A1 POLYMORPHIC FORM OF PITAVASTATIN CALCIUM FARMA GRS, D.O.O. (SI) 2013-03-21 WO disclosed
EP-2516437-A1 DISUBSTITUTED HETEROARYL-FUSED PYRIDINES Novartis AG (CH) 2012-10-31 EP disclosed
EP-2477966-A1 PROCESSES AND INTERMEDIATES Vertex Pharmaceuticals Incorporated (US) 2012-07-25 EP disclosed
EP-2437600-A1 BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS GlaxoSmithKline LLC (US) 2012-04-11 EP disclosed
EP-2427430-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS The Royal Institution for the Advancement of Learning / McGill University (CA) 2012-03-14 EP disclosed
EP-2406254-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI (FR) 2012-01-18 EP disclosed
WO-2007015824-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2007-02-08 WO disclosed
WO-2006122259-A1 OPTICAL RESOLUTION OF 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACID TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-11-16 WO disclosed
WO-2006122255-A1 PREGABALIN FREE OF ISOBUTYLGLUTARIC ACID AND A PROCESS FOR PREPARATION THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-11-16 WO disclosed
EP-1641752-A1 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA GLAXO GROUP LIMITED (GB) 2006-04-05 EP disclosed
WO-2006026489-A1 NOVEL DIAZAPHOSPHOLANE LIGANDS FOR ASYMMETRIC CATALYSIS THE DOW CHEMICAL COMPANY (US) 2006-03-09 WO disclosed
WO-2006023852-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS, INCORPORATED (US) 2006-03-02 WO disclosed
WO-2006017406-A1 CYANOAMIDINE P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN ABBOTT LABORATORIES (US) 2006-02-16 WO disclosed
WO-2004110997-A1 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA GLAXO GROUP LIMITED (GB) 2004-12-23 WO disclosed